LRMRNasdaqPharmaceutical PreparationsUS GAAP · USD

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing nomlabofusp for Friedreich's ataxia, a rare genetic disease that causes progressive disability. The company is focused on advancing the drug through clinical development and regulatory review, with an eventual goal of commercialization if approved.

Ask about the company
Operating profit (EBIT)-172m USD
−89.8 %y/y
Net income-166m USD
−105.5 %y/y
Free cash flow-113m USD
−59.0 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-200-150-100-500m USD2020: EBIT -43 m USD20202021: EBIT -50 m USD20212022: EBIT -37 m USD20222023: EBIT -42 m USD20232024: EBIT -91 m USD20242025: EBIT -172 m USD2025-172
RevenueOperating profit (EBIT)

Business

Share of revenue
Lead drug candidate100 %

Nomlabofusp is the company's main investigational therapy for Friedreich's ataxia.

Clinical development programs0 %

Open label and extension studies generate the clinical evidence needed for regulatory review.

Formulation development0 %

Work to transition from frozen solution to lyophilized product for commercialization.

Customers

Larimar does not currently sell commercial products; its near-term 'customers' are clinical trial participants, investigators, regulators, and future patients with Friedreich's ataxia. If approved, the commercial customer base would shift to specialty neurology and rare-disease treatment channels, with prescribing driven by disease severity and unmet need.

Clinical trial participants with Friedreich's ataxia

Patients enroll in studies to access investigational therapy and contribute efficacy and safety data.

Regulatory agencies

FDA, EMA, and MHRA review the development package, endpoint strategy, and safety data.

Future rare-disease prescribers and patients

If approved, neurologists and FA patients would use nomlabofusp as a disease-targeted therapy.

Potential strategic partners

Partners may provide capital, development support, or commercialization capabilities.

Strategy

The company is focused on advancing nomlabofusp toward regulatory approval, including continued interaction with FDA under the START pilot program. A key strategic step is converting the formulation to a lyophilized product intended for commercialization while building the evidence package around FXN concentration as a surrogate endpoint.

Regulatory path for accelerated approvalShort term

FDA alignment on endpoint strategy and safety package is critical to shorten time to market.

Clinical development of nomlabofuspShort term

Clinical data are needed to support efficacy, safety, and eventual commercialization.

Commercial formulation readinessMedium term

The lyophilized product is intended for commercialization and must be validated in development.

Capital preservation and financing flexibilityShort term

As a pre-revenue biotech, the company must fund ongoing R&D until approval or partnership.

Geography

Larimar is based in the United States and its development work is centered on U.S. regulatory interactions, especially with the FDA. It also engages with the EMA and MHRA, so its clinical and regulatory footprint is transatlantic even though it remains pre-commercial and has no disclosed product revenue geography.

Risks

Larimar faces the typical risks of a single-asset, pre-revenue biotech: clinical failure, regulatory delay, and financing dependence. Its business is especially exposed to endpoint acceptance and safety-package sufficiency because approval may depend on surrogate biomarker evidence rather than traditional long-term outcomes.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical development failure1Regulatory endpoint uncertainty2Manufacturing and formulation execution4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development failureImpact: CriticalLikelihood: Medium

    The company has no approved products, so value depends on nomlabofusp succeeding in trials.

    Exposure: Lead asset nomlabofusp

  2. Regulatory endpoint uncertaintyImpact: HighLikelihood: Low

    Accelerated approval may depend on FDA accepting FXN concentration as a surrogate endpoint.

    Exposure: BLA strategy and approval timing

  3. Financing riskImpact: High

    The company is pre-revenue and expects to fund operations through external capital.

    Exposure: Cash runway into 2026

  4. Manufacturing and formulation executionImpact: MediumLikelihood: Low

    Commercialization depends on successful transition to the lyophilized formulation.

    Exposure: Drug product comparability and scale-up

  5. Rare-disease trial executionImpact: Medium

    Small patient populations make enrollment, retention, and endpoint interpretation difficult.

    Exposure: FA clinical studies

Accounting

Judgemental items
Research and development accruals

Trial, manufacturing, and nonclinical costs are estimated before vendor invoices arrive.

Impact: Can shift quarterly R&D expense and operating loss

Stock-based compensation

A common expense in development-stage biotech companies with equity-heavy pay.

Impact: Affects reported operating expenses and net loss

Going-concern and liquidity disclosures

The company depends on external financing to fund operations until approval.

Impact: Important for assessing dilution and runway

Similar listed companies

Publicly listed companies with a comparable business focus.

Kalaris Therapeutics, Inc.

KLRS · Biological Products, (No Diagnostic Substances)

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

Filana Therapeutics, Inc

FLNA · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Liminatus Pharma, Inc.

LIMNW · Biological Products, (No Diagnostic Substances)

Damora Therapeutics, Inc.

DMRA · Pharmaceutical Preparations

Last updated: 24/09/2026

Larimar Therapeutics, Inc. (Nasdaq) – Pharmaceutical Preparations | Financial Analysis – Clarifo